Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Recurrence 1Ovarian Neoplasms 1Mesothelioma 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 171Radiotherapy 144Magnetic Resonance Spectroscopy 142Leuprolide 112Prednisone 108enzalutamide 102Radiosurgery 101Abiraterone Acetate 94Androgen Antagonists 91Goserelin 83bicalutamide 81gallium 68 PSMA-11 70Surveys and Questionnaires 63apalutamide 57Specimen Handling 56acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 55Radiation 47Gonadotropin-Releasing Hormone 45Standard of Care 44Biopsy 44Brachytherapy 42Radiotherapy, Intensity-Modulated 40Blood Specimen Collection 40darolutamide 39abiraterone 39cabazitaxel 35Exercise 35Carboplatin 33Pluvicto 32Triptorelin Pamoate 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Prostatic Neoplasms × TroVax × Clear all
NCT02390063 2020-02-10

Vaccination in Prostate Cancer (VANCE)

University of Oxford

Phase 1 Completed
40 enrolled
Genitourinary

Prostatic Neoplasms

NCT00448409 2016-03-17

Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer

The Methodist Hospital Research Institute

Phase 2 Completed
27 enrolled
Genitourinary

Prostatic Neoplasms

NCT00521274 2016-03-17

Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer

The Methodist Hospital Research Institute

Phase 2 Terminated
11 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡